| scholarly article | Q13442814 |
| P356 | DOI | 10.2337/DIABETES.48.2.377 |
| P698 | PubMed publication ID | 10334317 |
| P50 | author | Allan Flyvbjerg | Q49252518 |
| P2093 | author name string | J J Kopchick | |
| R Rasch | |||
| W F Bennett | |||
| J A Scarlett | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 377-382 | |
| P577 | publication date | 1999-02-01 | |
| P1433 | published in | Diabetes | Q895262 |
| P1476 | title | Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice | |
| P478 | volume | 48 |
| Q37236268 | Abnormal angiogenesis in diabetic nephropathy. |
| Q25257361 | Alterations of renal phenotype and gene expression profiles due to protein overload in NOD-related mouse strains |
| Q35791559 | Analysis of the Zucker Diabetic Fatty (ZDF) type 2 diabetic rat model suggests a neurotrophic role for insulin/IGF-I in diabetic autonomic neuropathy |
| Q40269064 | Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the development of diabetic nephropathy |
| Q33793187 | Autocrine and paracrine mechanisms in the early stages of diabetic nephropathy |
| Q34207694 | Biological effects of growth hormone and its antagonist |
| Q36620111 | Diabetic microangiopathy: IGFBP control endothelial cell growth by a common mechanism in spite of their species specificity and tissue peculiarity |
| Q40919215 | Disulfide linkage of growth hormone (GH) receptors (GHR) reflects GH-induced GHR dimerization. Association of JAK2 with the GHR is enhanced by receptor dimerization |
| Q51366821 | Effects of intensive glycemic control on serum levels of insulin-like growth factor-I and dehydroepiandrosterone sulfate in Type 2 diabetes mellitus. |
| Q37806614 | Endothelial dysfunction as a potential contributor in diabetic nephropathy |
| Q37619460 | Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications |
| Q57828018 | Extra-hepatic Acromegaly |
| Q44044518 | G120K-PEG, a human GH antagonist, decreases GH signal transduction in the liver of mice. |
| Q35581294 | Growth factors and the development of diabetic nephropathy |
| Q37754528 | Growth factors in diabetic complications |
| Q35762332 | Growth hormone and glucose metabolism: the model of the GH-receptor antagonists. |
| Q77148152 | Growth hormone increases the total number of cardiac myocyte nuclei in young rats but not in old rats |
| Q77648340 | Growth hormone influences the content and composition of collagen in the aorta from old rats |
| Q34349411 | Growth hormone receptor antagonists: discovery and potential uses |
| Q37214703 | Growth hormone receptor modulators |
| Q33639324 | Identification of differentially expressed genes in the kidneys of growth hormone transgenic mice |
| Q52956659 | Improvement of fracture healing by systemic administration of growth hormone and local application of insulin-like growth factor-1 and transforming growth factor-beta1. |
| Q35590849 | Inhibitory GH receptor extracellular domain monoclonal antibodies: three-dimensional epitope mapping |
| Q44209597 | Insulin-like growth factor-1 and transforming growth factor-beta1 accelerates osteotomy healing using polylactide-coated implants as a delivery system: a biomechanical and histological study in minipigs |
| Q46119541 | Local application of growth factors (insulin-like growth factor-1 and transforming growth factor-beta1) from a biodegradable poly(D,L-lactide) coating of osteosynthetic implants accelerates fracture healing in rats. |
| Q43816270 | Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist |
| Q40986521 | Novel Actions of Growth Hormone in Podocytes: Implications for Diabetic Nephropathy |
| Q40800058 | Pathophysiological Role of Growth Factors in Diabetic Kidney Disease: Focus on Innovative Therapy |
| Q38955048 | Pegvisomant: a growth hormone receptor antagonist used in the treatment of acromegaly |
| Q37036858 | Podocytopathy in diabetes: a metabolic and endocrine disorder |
| Q34349424 | Potential use of growth hormone receptor antagonist in the treatment of diabetic kidney disease |
| Q33554471 | The Glomerular Podocyte as a Target of Growth Hormone Action: Implications for the Pathogenesis of Diabetic Nephropathy |
| Q44536354 | The effects of a specific growth hormone antagonist on overnight insulin requirements and insulin sensitivity in young adults with Type 1 diabetes mellitus |
Search more.